HALO – Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.

HALO

$58.79

Name : Halozyme Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $7,262,504,960.00

EPSttm : 3.43

Halozyme Therapeutics, Inc.

$58.79

0.05%

$0.03

Float Short %

7.55

Margin Of Safety %

Put/Call OI Ratio

0.32

EPS Next Q Diff

-0.12

EPS Last/This Y

1.4

EPS This/Next Y

1.51

Price

58.79

Target Price

68.12

Analyst Recom

1.89

Performance Q

6.18

Relative Volume

1.07

Beta

1.26

Ticker: HALO

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-03-20	HALO	64.33	0.24	0.01	17860
2025-03-21	HALO	65.18	0.26	0.19	16889
2025-03-24	HALO	64	0.28	0.44	7402
2025-03-25	HALO	64.87	0.29	1.81	7640
2025-03-26	HALO	63.8	0.27	0.19	7580
2025-03-27	HALO	64.49	0.28	0.03	7655
2025-03-28	HALO	63.86	0.27	4.04	7808
2025-03-31	HALO	63.81	0.30	0.74	7985
2025-04-01	HALO	61.92	0.30	2.87	8068
2025-04-02	HALO	63.02	0.37	0.98	8497
2025-04-03	HALO	61.9	0.37	0.26	8509
2025-04-04	HALO	59.74	0.36	0.13	8584
2025-04-07	HALO	59.34	0.39	0.35	8289
2025-04-08	HALO	57.58	0.39	0.29	8313
2025-04-09	HALO	60.61	0.38	0.35	8471
2025-04-10	HALO	57.71	0.39	0.84	8399
2025-04-11	HALO	60.23	0.40	0.08	8439
2025-04-14	HALO	61.19	0.38	0.18	8675
2025-04-15	HALO	61.28	0.32	0.10	10299
2025-04-16	HALO	58.78	0.32	1.19	10337
2025-04-17	HALO	58.79	0.32	0.12	10428
2025-04-18	HALO	58.79	0.32	0.12	10428
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-03-20	HALO	64.32	19.7	-	4.93
2025-03-21	HALO	65.18	19.7	-	4.93
2025-03-24	HALO	64.02	19.7	-	4.93
2025-03-25	HALO	64.84	19.7	-	4.93
2025-03-26	HALO	63.82	19.7	-	4.93
2025-03-27	HALO	64.47	21.7	-	4.90
2025-03-28	HALO	63.84	21.7	-	4.90
2025-03-31	HALO	63.79	21.7	-	4.90
2025-04-01	HALO	61.87	21.7	-	4.90
2025-04-02	HALO	63.02	21.7	-	4.90
2025-04-03	HALO	61.92	21.7	-	4.90
2025-04-04	HALO	59.70	21.7	-	4.90
2025-04-07	HALO	59.34	21.7	-	4.90
2025-04-08	HALO	57.54	21.7	-	4.90
2025-04-09	HALO	60.65	21.7	-	4.90
2025-04-10	HALO	57.71	21.7	-	4.90
2025-04-11	HALO	60.23	21.7	-	4.90
2025-04-14	HALO	61.39	21.7	-	4.90
2025-04-15	HALO	61.28	21.7	-	4.90
2025-04-16	HALO	58.84	21.7	-	4.90
2025-04-17	HALO	58.79	21.7	-	4.90
2025-04-18	HALO	58.79	21.7	-	4.90
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-03-20	HALO	-7.37	-2.46	8.01
2025-03-21	HALO	-7.37	-2.46	8.01
2025-03-24	HALO	-7.35	-2.37	7.98
2025-03-25	HALO	-7.35	-2.37	7.98
2025-03-26	HALO	-7.35	-2.37	8.25
2025-03-27	HALO	-5.48	-2.37	8.25
2025-03-28	HALO	-5.48	-2.37	8.25
2025-03-31	HALO	-5.93	-2.34	8.24
2025-04-01	HALO	-5.93	-2.34	8.24
2025-04-02	HALO	-5.96	-2.34	8.24
2025-04-03	HALO	-5.96	-2.34	8.24
2025-04-04	HALO	-5.96	-2.34	8.24
2025-04-07	HALO	-5.96	-2.33	8.24
2025-04-08	HALO	-5.91	-2.33	8.24
2025-04-09	HALO	-5.91	-2.33	8.24
2025-04-10	HALO	-4.53	-2.33	7.55
2025-04-11	HALO	-4.53	-2.33	7.55
2025-04-14	HALO	-4.53	-2.32	7.55
2025-04-15	HALO	-4.53	-2.32	7.55
2025-04-16	HALO	-4.53	-2.32	7.55
2025-04-17	HALO	-3.12	-2.32	7.55
2025-04-18	HALO	-3.12	-2.32	7.55
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

1.26

Avg. EPS Est. Current Quarter

0.96

Avg. EPS Est. Next Quarter

1.14

Insider Transactions

-3.12

Institutional Transactions

-2.32

Beta

1.26

Average Sales Estimate Current Quarter

231

Average Sales Estimate Next Quarter

279

Fair Value

85.17

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

10.9

Max Drawdown 5-Year %

-49.1

Target Price

68.12

P/E

17.13

Forward P/E

8.42

PEG

0.63

P/S

7.15

P/B

19.9

P/Free Cash Flow

15.51

EPS

3.43

Average EPS Est. Cur. Y

4.9

EPS Next Y. (Est.)

6.41

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

43.74

Relative Volume

1.07

Return on Equity vs Sector %

102.1

Return on Equity vs Industry %

115.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.03

EBIT Estimation

Halozyme Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 350

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

stock quote shares HALO – Halozyme Therapeutics, Inc. Stock Price stock today

news today HALO – Halozyme Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch HALO – Halozyme Therapeutics, Inc. yahoo finance google finance

stock history HALO – Halozyme Therapeutics, Inc. invest stock market

stock prices HALO premarket after hours

ticker HALO fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

HALO – Halozyme Therapeutics, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: HALO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y